On June 13, 2024, the Bombay High Court granted Glenmark an interim injunction against Gleck Pharma in a trademark dispute over “ZITA-MET” and “XIGAMET”. The court found that the similarities between the trademarks could confuse consumers, leading to potential health risks, and applied strict standards to prevent such confusion.
Read more about Diabetic Product XigaMet Loses to ZitaMet Under Heightened Pharma Trademark ScrutinyTag: Glenmark Pharmaceuticals
Drug Humira turns Rheumatic for Abbott Biotechnology
The Indian Patent Office set aside Abbott Biotechnology’s Humira patent after Glenmark’s pre-grant opposition, citing lack of inventive step and insufficient disclosure. This legal dispute underscores ongoing challenges to Humira patents both in India and globally.
Read more about Drug Humira turns Rheumatic for Abbott Biotechnology